The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
|Articles|December 2, 2021
Pharmacy Clinical Pearl of the Day: Churg-Strauss Syndrome
Author(s)Saro Arakelians, PharmD
Churg-Strauss syndrome causes inflammation that can restrict blood flow to organs and tissues.
Advertisement
Clinical Pearl of the Day: Churg-Strauss Syndrome
Churg-Strauss syndrome is a disorder marked by blood vessel inflammation.
Insight:
- This inflammation can restrict blood flow to organs and tissues, sometimes permanently damaging them.
- This condition is also known as eosinophilic granulomatosis with polyangiitis (EGPA).
- Adult-onset asthma is the most common sign of Churg-Strauss syndrome.
- Symptoms may include loss of appetite, weight loss, joint and muscle pain, abdominal pain, weakness, fatigue, rash, skin sores, pain, numbness and tingling in the hands and feet.
- Complications may include peripheral nerve damage, heart disease, and kidney damage.
- Diagnosis may include blood test, imaging tests, and biopsy of the affected tissue.
- Treatment may include corticosteroids, such as Prednisone, to reduce inflammation; Mepolizumab (Nucala); and other medications such as azathioprine (Azasan, Imuran), benralizumab (Fasenra), cyclophosphamide, methotrexate (Trexall), and rituximab (Rituxan).
Sources:
Advertisement
Related to this article
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.
Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Finerenone Expands MRA Options as Pharmacists Address Underrecognized HFpEF
2
Finerenone in Heart Failure: Evidence and Practice a Year Later
3
Pelacarsen, Ziltivekimab Miss CV End Points: What to Know
4
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
5